Table 3.
Change in treatment persistence over time by 3-year running cohort: time-to-event analysis
| Treatment | 2010–2011 | 2010–2012 | 2011–2013 | 2012–2014 | 2013–2015 | 2014–2016 | 2015–2017 | 2016–2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Persistence, months, median (95% CI); Q3 (95% CI) | n | Persistence, months, median (95 CI);Q3 (95 CI) | n | Persistence, months, median (95% CI); Q3 (95% CI) | n | Persistence, months, median (95% CI); Q3 (95% CI) | n | Persistence, months, median (95% CI); Q3 (95% CI) | n | Persistence, months, median (95% CI); Q3 (95% CI) | n | Persistence, months, median (95% CI); Q3 (95% CI) | n | Persistence, months, median (95% CI); Q3 (95% CI) | |
| Adalimumab | 109 |
18.7 (13.7–31.5); 8.0 (5.5–10.3) |
206 |
20.2 (15.6–30.8); 7.0 (5.7–9.4) |
261 |
18.9 (13.8–26.4); 5.8 (4.8–7.8) |
338 |
18.4 (15.0–25.2); 6.6 (5.7–8.6) |
395 |
15.3 (13.8–19.0); 6.3 (5.5–7.6) |
516 |
16.8 (14.6–21.0); 6.2 (5.5–7.6) |
596 |
18.3 (14.0–23.0); 6.1 (5.4–6.9) |
620 |
23.5 (18.7–∞); 7.3 (6.1–8.6) |
| Etanercept | 105 |
9.6 (7.0–16.3); 3.9 (3.4–5.6) |
173 |
13.2 (8.9–17.5); 3.9 (3.5–5.7) |
228 |
15.1 (11.6–19.2); 5.5 (3.8–7.3) |
279 |
16.3 (12.7–20.7); 5.6 (4.2–7.3) |
302 |
14.9 (12.1–19.0); 5.7 (4.5–7.3) |
288 |
10.8 (8.9–12.8); 4.6 (3.8–5.6) |
398 |
13.3 (11.3–17.6); 5.5 (4.7–6.4) |
568 |
18.7 (14.4–∞); 6.6 (5.7–7.6) |
| Ixekizumab | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 0 | – | 21 |
NRa; NRa |
50 |
NRa; 13.4 (11.9–∞) |
| Secukinumab | 0 | – | 0 | – | 0 | – | 0 | – | 37 |
NR; 21.5 (10.4–31.8) |
184 |
31.8 (22.5–∞); 12.3 (8.9–15.7) |
315 |
NRa; 11.8 (10.0–15.2) |
359 |
NRa; 12.0 (10.3–14.5) |
| Ustekinumab | 50 |
62.3 (45.6–∞); 23.2 (8.3–55.4) |
81 |
59.1 (45.1–84.2); 18.6 (10.6–27.6) |
105 |
50.3 (32.6–63.5); 15.8 (10.8–27.5) |
123 |
32.2 (23.7–47.7); 12.4 (9.5–15.5) |
171 |
29.1 (19.0–36.8); 11.9 (9.6–14.3) |
224 |
32.7 (21.2–49.3); 11.9 (9.2–13.7) |
269 |
NRa; 12.6 (11.0–16.9) |
279 |
NRa; 15.6 (12.1–∞) |
Three-year running cohort includes the year before and the year after
a50 patients did not discontinue treatment (equivalent to median persistence) within the time frame of the study